Peptide Therapeutics intermediate
Milestone 017: Oligopeptide Research Reference
2022: Tirzepatide (Mounjaro) approved. Dual GIP/GLP-1 agonist with 22.5% weight loss. This peptide or oligopeptide is studied for its biological activity, st...
By Encyclopeptide Editorial | 1 min read
milestone-017 peptide research
Overview
2022: Tirzepatide (Mounjaro) approved. Dual GIP/GLP-1 agonist with 22.5% weight loss.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Milestone 017” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Milestone 017: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept